Epcoritamab for diffuse large B-cell lymphoma after two previous treatments

Epcoritamab is currently in development for treatment of diffuse large B-cell lymphoma (DLBCL).
DLBCL is a cancer of B cells (a type of immune cell) and the most common type of fast-growing
non-Hodgkin’s lymphoma (NHL). In DLBCL, the body makes abnormal B cells which build up in
lymph nodes or other body organs. The affected lymphocytes start to divide before they are fully
mature and lose their infection-fighting properties, which makes the body more vulnerable to
infection. High incidence of disease relapsed/refractory occurs after treatment with currently
available monoclonal antibody (mAb) treatments. Eporitamab could provide an additional
treatment option for these individuals.